{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-078736","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.326756+00:00","generated_at":"2026-05-31T04:46:26.468711+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kyverna appoints Warner Biddle CEO, Christi Shaw to board; Maag resigns","bullets":["Warner Biddle appointed CEO and Class III director, effective Sept 16; previously SVP Global Head of Commercial at Kite Pharma.","Biddle receives 2,579,259-share option (4-year vest, 1-yr cliff), $625K salary, $650K sign-on bonus, and up to $150K relocation.","Peter Maag, Ph.D. resigned as CEO and director Sept 13; will provide contractor services for up to 6 mo at $45,833/mo plus $550K severance.","Christi Shaw appointed Class II director; granted option for $350K in shares vesting over 36 months; succeeded Brian Kotzin, who resigned.","Company adopted 2024 Inducement Equity Incentive Plan reserving 4M shares for new-hire equity grants, used for Biddle's option."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-078736","json":"https://secwatch.observer/filing/0001213900-24-078736.json","markdown":"https://secwatch.observer/filing/0001213900-24-078736.md","text":"https://secwatch.observer/filing/0001213900-24-078736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000121390024078736/0001213900-24-078736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000121390024078736/ea0214607-8k_kyverna.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:46:26.468711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04e58ae726","claim":"Warner Biddle was appointed as Chief Executive Officer and Class III director at Kyverna Therapeutics, Inc..","evidence_excerpt":"appointed Warner Biddle as the Company’s Chief Executive Officer and as a Class III director of the Company, in each case effective September 16, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1994702/000121390024078736/0001213900-24-078736-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}